Lilly to buy Massachusetts biopharma company for $3.2B
Eli Lilly and Co. said Monday it has agreed to buy a Massachusetts-based biopharmaceutical company that is developing therapies for inflammatory bowel disease and other chronic diseases for $3.2 billion. Indianapolis-based Lilly said it will acquire...... Read More